186 related articles for article (PubMed ID: 19436291)
21. Genetic Susceptibility to Prostate Cancer: Prostate-specific Antigen and its Interaction with the Androgen Receptor (United States).
Sieh W; Edwards KL; Fitzpatrick AL; Srinouanprachanh SL; Farin FM; Monks SA; Kronmal RA; Eaton DL
Cancer Causes Control; 2006 Mar; 17(2):187-97. PubMed ID: 16425097
[TBL] [Abstract][Full Text] [Related]
22. Association of elevated interleukin-33 serum levels with tumorstages in patients with prostate cancer.
Chatrabnous N; Jafarzadeh A; Ghaderi A; Ariafar A; Aminizadeh N; Ghassabi F; Nemati M
Eur Cytokine Netw; 2019 Dec; 30(4):144-150. PubMed ID: 32096476
[TBL] [Abstract][Full Text] [Related]
23. Replication study of 34 common SNPs associated with prostate cancer in the Romanian population.
Jinga V; Csiki IE; Manolescu A; Iordache P; Mates IN; Radavoi D; Rascu S; Badescu D; Badea P; Mates D
J Cell Mol Med; 2016 Apr; 20(4):594-600. PubMed ID: 26773531
[TBL] [Abstract][Full Text] [Related]
24. ARE-I polymorphism on PSA gene in prostate cancer patients of a Turkish population.
Kalay E; Ergen A; Narter F; Agaçhan B; Görmüs U; Yigit N; Isbir T
Anticancer Res; 2009 Apr; 29(4):1395-8. PubMed ID: 19414393
[TBL] [Abstract][Full Text] [Related]
25. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Miller PD; Eardley I; Kirby RS
Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
[TBL] [Abstract][Full Text] [Related]
26. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
Wang W; Yuasa T; Tsuchiya N; Ma Z; Maita S; Narita S; Kumazawa T; Inoue T; Tsuruta H; Horikawa Y; Saito M; Hu W; Ogawa O; Habuchi T
Int J Cancer; 2009 Dec; 125(12):2836-43. PubMed ID: 19585577
[TBL] [Abstract][Full Text] [Related]
27. Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels.
Licastro F; Bertaccini A; Porcellini E; Chiappelli M; Pernetti R; Sanguedolce F; Marchiori D; Martorana G
Anticancer Res; 2008; 28(1B):395-9. PubMed ID: 18383875
[TBL] [Abstract][Full Text] [Related]
28. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
29. Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma.
Fernandez-Pol JA; Fletcher JW; Hamilton PD; Klos DJ
Anticancer Res; 1997; 17(3A):1519-30. PubMed ID: 9179190
[TBL] [Abstract][Full Text] [Related]
30. Association of endothelin-1 gene single-nucleotide polymorphisms and haplotypes with risk of hormone refractory prostate cancer.
Xu D; Wang X; Lou Y
Pharmazie; 2017 Feb; 72(2):103-106. PubMed ID: 29441862
[TBL] [Abstract][Full Text] [Related]
31. Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer.
Wang X; An P; Zeng J; Liu X; Wang B; Fang X; Wang F; Ren G; Min J
Oncotarget; 2017 Mar; 8(11):17862-17872. PubMed ID: 28160568
[TBL] [Abstract][Full Text] [Related]
32. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
[TBL] [Abstract][Full Text] [Related]
33. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
34. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men.
Beebe-Dimmer JL; Lange LA; Cain JE; Lewis RC; Ray AM; Sarma AV; Lange EM; Cooney KA
Prostate Cancer Prostatic Dis; 2006; 9(1):50-5. PubMed ID: 16247489
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.
Li W; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Melander O; Ulmert D; Lilja H; Klein RJ
Prostate; 2020 Dec; 80(16):1405-1412. PubMed ID: 32914890
[TBL] [Abstract][Full Text] [Related]
37. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
[TBL] [Abstract][Full Text] [Related]
38. Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk.
Nimptsch K; Aleksandrova K; Boeing H; Janke J; Lee YA; Jenab M; Bueno-de-Mesquita HB; Jansen EH; Tsilidis KK; Trichopoulou A; Weiderpass E; Wu C; Overvad K; Tjønneland A; Boutron-Ruault MC; Dossus L; Racine A; Kaaks R; Canzian F; Lagiou P; Trichopoulos D; Palli D; Agnoli C; Tumino R; Vineis P; Panico S; Johansson A; Van Guelpen B; Khaw KT; Wareham N; Peeters PH; Quirós JR; Venceslá García A; Molina-Montes E; Dorronsoro M; Chirlaque MD; Barricarte Gurrea A; Key TJ; Duarte-Salles T; Stepien M; Gunter MJ; Riboli E; Pischon T
Int J Cancer; 2015 Mar; 136(5):1181-92. PubMed ID: 25043606
[TBL] [Abstract][Full Text] [Related]
39. Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.
Knipe DW; Evans DM; Kemp JP; Eeles R; Easton DF; Kote-Jarai Z; Al Olama AA; Benlloch S; Donovan JL; Hamdy FC; Neal DE; Smith GD; Lathrop M; Martin RM
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1356-1365. PubMed ID: 24753544
[TBL] [Abstract][Full Text] [Related]
40. C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitis.
Claushuis TA; de Vries MK; van der Weijden MA; Visman IM; Nurmohamed MT; Twisk JW; Van der Horst-Bruinsma IE; Crusius JB
Clin Exp Rheumatol; 2015; 33(2):159-65. PubMed ID: 25603416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
